Eikon Therapeutics develops new medicines using advanced technologies like single-molecule tracking and high-performance computing to accelerate drug discovery and development.

Abridge uses generative AI to convert patient-clinician conversations into structured clinical note drafts in real-time, with plans to support large-scale health system rollouts and create additional value for patients, clinicians, and health systems.